What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence presented indicates that eptinezumab has comparable clinical effectiveness to existing treatments such as erenumab, fremanezumab, and galcanezumab, based on an indirect comparison through a network meta-analysis. However, the absence of direct head-to-head trials limits the strength of this evidence, preventing a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
Eptinezumab is indicated as cost-effective when compared to other treatments, with a cost comparison suggesting similar costs and health benefits to existing options. The presence of a commercial arrangement further supports its economic viability, justifying a strong rating.
Is there quality-of-life evidence payers weigh? — Quality of life
The document discusses the significant impact of migraine on quality of life, and the need for effective preventive treatments that can improve this aspect. While specific HRQoL data from validated instruments are not detailed, the overall context suggests a moderate improvement in quality of life for patients using eptinezumab.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The document indicates that eptinezumab has a very good safety profile, with adverse events being mostly mild or moderate. This suggests a favorable tolerability compared to existing therapies, warranting a strong rating.
Was the drug compared against what payers expect? — Comparator Selection
The comparators selected for the evaluation (erenumab, fremanezumab, and galcanezumab) are appropriate and relevant, as they are established treatments for migraine prevention. The document confirms that these comparators align well with the intended patient population.
Is the population defined the way payers need it? — Patient Population and Subgroups
The patient population for eptinezumab is well-defined, focusing on adults with chronic or episodic migraines who have not responded to at least three preventive treatments. However, there are some limitations in subgroup analyses, preventing a higher rating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Eptinezumab can be integrated into existing care pathways, although it requires administration in a hospital setting. This indicates a moderate level of disruption but is manageable within current practices.
Are the wider system costs understood? — Resource Use and Cost Implications
The document suggests that the budget impact of eptinezumab is manageable and aligns with planning, indicating a favorable resource use profile. The presence of a commercial arrangement further supports its economic feasibility.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base includes a network meta-analysis and input from external assessment groups, which strengthens the credibility of the findings. However, the reliance on indirect comparisons introduces some methodological concerns.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the indirect comparisons, the overall context of unmet need and the potential for improved access to treatment for patients with difficulties self-administering injections mitigates these concerns.
